文献速递冠心病外科

替格瑞洛停药后血小板功能恢复与急诊冠脉手术时机

Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

前瞻性观察25例等待急诊冠脉搭桥且服用替格瑞洛+阿司匹林的患者,停药后12–96小时用阻抗聚集法测血小板聚集。停药72小时后平均ADP诱导聚集为38±23 U,高于既往 suggested 22 U切点,但个体差异大(4–88 U),6/24(25%)仍<22 U;体外补充血小板浓缩物未改善聚集。

要点

  • 停药72小时后多数患者ADP诱导聚集可接受,但个体差异大。
  • 25%患者停药72小时后ADP诱导聚集仍低于22 U切点。
  • 体外补充血小板浓缩物未改善ADP诱导聚集。

核心结论

  • 停药72小时后多数患者ADP诱导聚集可接受,但个体差异大,血小板功能检测可能有助于确定手术时机。
  • 体外补充血小板浓缩物未改善替格瑞洛停药后的ADP诱导聚集。

研究设计与样本

  • 前瞻性观察研究,纳入25例接受急诊冠脉搭桥且服用替格瑞洛+阿司匹林的患者。
  • 停药后12–96小时五个时间点用阻抗聚集法评估血小板聚集,其中15例测试体外补充血小板浓缩物的效果。

主要发现

  • 停药后平均ADP诱导血小板聚集逐渐升高,72小时为38±23 U,高于既往 suggested 22 U切点。
  • 72小时个体差异大(范围4–88 U),6/24例(25%)仍<22 U。
  • 体外给予血小板浓缩物未在任何时间点改善ADP诱导聚集。

关键数值与推荐

  • 既往 suggested 切点为22 U,用于判断患者可无增加出血风险地手术。
  • 停药72小时平均ADP诱导聚集38±23 U,范围4–88 U,6/24例(25%)<22 U。

临床怎么用

  • 替格瑞洛停药后72小时多数患者ADP诱导聚集可接受,但需注意个体差异。
  • 对近期停用替格瑞洛的急诊冠脉手术患者,血小板功能检测可能有助于手术时机决策。

局限性

  • 样本量小(25例),仅15例测试体外血小板浓缩物补充。
  • 单中心观察性研究,未报告临床出血结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dual antiplatelet therapy with ticagrelor and aspirin is associated with an increased risk of perioperative bleeding complications. Current guidelines recommend therefore discontinuation of ticagrelor 5 days before surgery to allow sufficient recovery of platelet function. It is not known how the time to recovery varies between individual patients after discontinuation of ticagrelor. METHODS: Twenty-five patients accepted for urgent coronary artery bypass surgery and treated with ticagrelor and aspirin were included in a prospective observational study. Platelet aggregation was evaluated with impedance aggregometry at five timepoints 12-96 h after discontinuation of ticagrelor. In a subset of patients ( n = 15), we also tested the ex vivo efficacy of platelet concentrate supplementation on platelet aggregation. RESULTS: There was a gradual increase in mean adenosine diphosphate-induced platelet aggregation after discontinuation of ticagrelor. After 72 h, mean aggregation was 38 ±23 aggregation units (U), which is above a previously suggested cut-off of 22 U, when patients can be operated without increased bleeding risk. However, there was a large interindividual variability (range 4‒88 U at 72 h) and 6/24 patients (25%) had <22 U after 72 h. Ex vivo administration of platelet concentrate did not improve adenosine diphosphate-induced aggregation at any timepoint after ticagrelor discontinuation. CONCLUSIONS: Adenosine diphosphate-induced aggregation was acceptable after 72 h in the majority of patients but with a large interindividual variability. Due to the large variability, platelet function testing may prove to be a valuable tool in timing of surgery in patients with ongoing or recently stopped ticagrelor treatment. Adenosine diphosphate-induced aggregation was not improved by addition of platelet concentrate.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Hansson EC, Malm CJ, Hesse C, et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardiothorac Surg. 2017. PMID: 28007881. doi:10.1093/ejcts/ezw373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。